FGFR2-amplified gastroesophageal adenocarcinoma is a distinct genomic class: Lessons learned from a liquid biopsy platform.

Authors

null

Bushra Shariff

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

Bushra Shariff , Reagan Barnett , Farshid Dayyani , Steven Brad Maron , Samuel J Klempner , Jude Masannat , Leylah Drusbosky , Rory Mcgriskin , Rutika Mehta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Translational Research

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 429)

DOI

10.1200/JCO.2023.41.4_suppl.429

Abstract #

429

Poster Bd #

J13

Abstract Disclosures

Similar Posters

Poster

2019 Gastrointestinal Cancers Symposium

Genomic alterations in appendiceal carcinoma using circulating DNA.

Genomic alterations in appendiceal carcinoma using circulating DNA.

First Author: Walid Labib Shaib

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Circulating tumor DNA-based genomic landscape of early-onset pancreatic cancer.

Circulating tumor DNA-based genomic landscape of early-onset pancreatic cancer.

First Author: Reagan Barnett

Poster

2019 Gastrointestinal Cancers Symposium

<em>FGFR2-</em>altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.

FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.

First Author: Samuel Jacob Klempner

Poster

2017 Gastrointestinal Cancers Symposium

Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.

Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.

First Author: Steven Brad Maron